These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
645 related articles for article (PubMed ID: 22806960)
1. Liver X receptors orchestrate osteoblast/osteoclast crosstalk and counteract pathologic bone loss. Kleyer A; Scholtysek C; Bottesch E; Hillienhof U; Beyer C; Distler JH; Tuckermann JP; Schett G; Krönke G J Bone Miner Res; 2012 Dec; 27(12):2442-51. PubMed ID: 22806960 [TBL] [Abstract][Full Text] [Related]
2. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921 [TBL] [Abstract][Full Text] [Related]
3. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637 [TBL] [Abstract][Full Text] [Related]
5. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo. Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094 [TBL] [Abstract][Full Text] [Related]
6. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185 [TBL] [Abstract][Full Text] [Related]
7. Anti-c-fms Antibody Prevents Osteoclast Formation and Bone Resorption in Co-Culture of Osteoblasts and Osteoclast Precursors In Vitro and in Ovariectomized Mice. Nara Y; Kitaura H; Ogawa S; Shen WR; Qi J; Ohori F; Noguchi T; Marahleh A; Pramusita A; Kinjo R; Mizoguchi I Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32854340 [TBL] [Abstract][Full Text] [Related]
8. Yukmijihwang-Tang Suppresses Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-Induced Osteoclast Differentiation and Prevents Ovariectomy (OVX)-Mediated Bone Loss. Han SY; Kim YK Molecules; 2021 Dec; 26(24):. PubMed ID: 34946658 [TBL] [Abstract][Full Text] [Related]
9. [Effect of Erigeron Breviscapus on the expression of OPG/RANKL/RANK in osteoblasts and pre-osteoclasts in vitro]. Liu CG; Luo QX; Ling TY; Mo YY; Cheng ZL; Huang SG; Mo H Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Dec; 33(12):1658-64. PubMed ID: 24517065 [TBL] [Abstract][Full Text] [Related]
10. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts. Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286 [TBL] [Abstract][Full Text] [Related]
11. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644 [TBL] [Abstract][Full Text] [Related]
12. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin. Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296 [TBL] [Abstract][Full Text] [Related]
13. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. Liu XH; Kirschenbaum A; Yao S; Levine AC Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359 [TBL] [Abstract][Full Text] [Related]
14. Differentiation and functions of osteoclasts and odontoclasts in mineralized tissue resorption. Sasaki T Microsc Res Tech; 2003 Aug; 61(6):483-95. PubMed ID: 12879416 [TBL] [Abstract][Full Text] [Related]
15. [Establish mouse osteoblast -osteoclast cell co-culture system in a Transwell chamber]. Mo GY; Zhang SC; Li YX; Guo HZ; Guo DQ; Li DX; Tang YC; Mo L; Luo PJ; Ma YH Zhongguo Gu Shang; 2018 Mar; 31(3):241-247. PubMed ID: 29600675 [TBL] [Abstract][Full Text] [Related]
16. Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions. Fioramonti M; Santini D; Iuliani M; Ribelli G; Manca P; Papapietro N; Spiezia F; Vincenzi B; Denaro V; Russo A; Tonini G; Pantano F Oncotarget; 2017 Mar; 8(12):20113-20121. PubMed ID: 28223547 [TBL] [Abstract][Full Text] [Related]
17. Liver X receptor activation inhibits osteoclastogenesis by suppressing NF-κB activity and c-Fos induction and prevents inflammatory bone loss in mice. Kim HJ; Yoon KA; Yoon HJ; Hong JM; Lee MJ; Lee IK; Kim SY J Leukoc Biol; 2013 Jul; 94(1):99-107. PubMed ID: 23657115 [TBL] [Abstract][Full Text] [Related]
18. Osteoclast differentiation by RANKL and OPG signaling pathways. Udagawa N; Koide M; Nakamura M; Nakamichi Y; Yamashita T; Uehara S; Kobayashi Y; Furuya Y; Yasuda H; Fukuda C; Tsuda E J Bone Miner Metab; 2021 Jan; 39(1):19-26. PubMed ID: 33079279 [TBL] [Abstract][Full Text] [Related]
19. Production of IL-7 is increased in ovariectomized mice, but not RANKL mRNA expression by osteoblasts/stromal cells in bone, and IL-7 enhances generation of osteoclast precursors in vitro. Sato T; Watanabe K; Masuhara M; Hada N; Hakeda Y J Bone Miner Metab; 2007; 25(1):19-27. PubMed ID: 17187190 [TBL] [Abstract][Full Text] [Related]
20. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL. Kim HN; Ha H; Lee JH; Jung K; Yang D; Woo KM; Lee ZH Eur J Pharmacol; 2009 Nov; 623(1-3):22-9. PubMed ID: 19766111 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]